nafamostat has been researched along with Myocardial Infarction in 6 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated the ideal dosage and efficacy of nafamostat mesilate for use with ECMO in patients with acute cardiac or respiratory failure." | 1.37 | Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. ( Han, SJ; Hong, KS; Kim, HS; Kim, KI; Lee, SH; Lee, WK; Whang, SM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| La Bonte, LR | 2 |
| Dokken, B | 1 |
| Davis-Gorman, G | 2 |
| Stahl, GL | 2 |
| McDonagh, PF | 2 |
| Han, SJ | 1 |
| Kim, HS | 1 |
| Kim, KI | 1 |
| Whang, SM | 1 |
| Hong, KS | 1 |
| Lee, WK | 1 |
| Lee, SH | 1 |
| Noda, K | 2 |
| Sasaguri, M | 2 |
| Ideishi, M | 2 |
| Ikeda, M | 2 |
| Arakawa, K | 2 |
| Ihno, T | 1 |
| Nakagawa, T | 1 |
| Furukawa, H | 1 |
| Shimizu, K | 1 |
| Egi, K | 1 |
| Maemura, T | 1 |
| Motomiya, T | 1 |
6 other studies available for nafamostat and Myocardial Infarction
| Article | Year |
|---|---|
The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart.
Topics: Animals; Antibodies, Monoclonal; Benzamidines; Complement C3; Complement Inactivating Agents; Diabet | 2009 |
Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation.
Topics: Acute Disease; Anticoagulants; Benzamidines; Dose-Response Relationship, Drug; Extracorporeal Membra | 2011 |
Complement inhibition reduces injury in the type 2 diabetic heart following ischemia and reperfusion.
Topics: Animals; Benzamidines; Blood Cell Count; Blood Glucose; Blood Pressure; CD11b Antigen; Cell Adhesion | 2008 |
Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs.
Topics: Angiotensin II; Animals; Benzamidines; Bradykinin; Captopril; Dogs; Guanidines; Hemodynamics; Male; | 1993 |
Various problems during long-term percutaneous cardiopulmonary support.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Benzamidines; Blood Transfusion, Autologous; Cardiop | 1997 |
Cardioprotection of ACE inhibitor in ischemic heart is not dependent on the local angiotensin II formation.
Topics: Angiotensin II; Animals; Benzamidines; Blood Pressure; Bradykinin; Captopril; Cardiac Output; Corona | 1992 |